CTRI/2011/06/001837进行中（未招募）3 期
A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer - Nil
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients at least 18 years old with histopathologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.
- •2. Patients must have received no prior chemotherapy for pancreatic cancer.
- •3. Measurable disease, defined as lesions that can be accurately measured in at least 1 dimension with longest diameter (LD) >= 20 mm using conventional techniques or >= 10 mm with spiral computed tomography (CT) scan; measurable lymph nodes must be >= 15 mm in the short axis.
- •4. ECOG Performance Status of 0, 1, or 2.
- •5. Patients must have adequate renal function and serum creatinine <=2.0 mg/dL, with a minimum calculated glomerular filtration rate (GFR) of 40 mL/min.
- •6. Patients must have adequate liver function as defined by total bilirubin <= 2.0 mg/dL and transaminase levels no higher than 3.0 times the institutions upper limit of normal (ULN). Patients with hepatic metastases may have transaminase levels of up to 5.0 times the ULN.
- •7. All patients must have a serum albumin >= 3.0 g/dL.
- •8. Patients must have adequate bone marrow (BM) function as defined by a granulocyte count >= 1,500/mm3, a platelet count >= 100,000/mm3, and hemoglobin 9 g/dL.
- •9. Disease-free period of more than 5 years from prior malignancies other than pancreas (except curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix and ductal carcinoma in situ [DCIS] breast disease).
- •10. Adequate contraceptive regimen (including prescription oral contraceptives [birth control pills], contraceptive injections, intrauterine device [IUD], double-barrier method [spermicidal jelly or foam with condoms or diaphragm], contraceptive patch, or surgical sterilization) before entry and throughout the study for female patients of reproductive potential or female partners of male patients. Male patients with female partners with reproductive potential will utilize birth control methods (e.g., condom use) while participating in this trial;
- •11.Female patient with reproductive potential must have a negative urine beta human chorionic gonadotropin pregnancy test at Screening.
- •12.Willing to adhere to the prohibitions and restrictions specified in this protocol.
- •13.Patient must have signed an informed consent document.
排除标准
- •Patients with any of the following will not be enrolled in the study:
- •1. Patients with unresectable locally advanced disease without evidence of disease elsewhere;
- •2. Life expectancy of less than 12 weeks;
- •3. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension or seizure disorder;
- •4. Active infection not adequately responding to appropriate therapy.
- •5. Symptomatic or clinically evident ascites.
- •6. Serum sodium less than 130 mEq/L or conditions that may predispose patients to hyponatremia (e.g., previous syndrome of inappropriate antidiuretic hormone hypersecretion [SIADH], chronic diuretic use, etc.)
- •7. Female patients who are pregnant or lactating.
- •8. Major surgery without full recovery or major surgery within 3 weeks of ON 01910.Na treatment start.
- •9. Evidence of brain metastases. A CT scan or magnetic resonance imaging (MRI) of the brain should be obtained in patients with symptoms suggestive of brain metastases;
- •10. Any concurrent administration and/or prior administration within 4 weeks of the first dose of study drug, of an investigational agent, chemotherapy, radiotherapy, or immunotherapy.
- •11. Psychiatric illness/social situations that would limit the patients ability to tolerate and/or comply with study requirements, or inability to comply with study and/or follow-up procedures (e.g., drug addition, chronic non-compliance, etc.).
研究者
相似试验
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na in combination with Gemcitabine vs. Gemcitabine alone in patients with a previously untreated metastatic pancreatic cancer.Metastatic Pancreatic CancerMedDRA version: 15.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2012-003547-29-HUOnconova Therapeutics Inc.364
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatments.EUCTR2010-019755-21-BEOnconova Therapeutics Inc.270
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatmentsMyelodysplastic syndrome with excess blastsMedDRA version: 14.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019755-21-ITONCONOVA THERAPEUTICS270
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatments.EUCTR2010-019755-21-ESOnconova Therapeutics Inc270
进行中（未招募）
1 期
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome - SICCANOVEKeratoconjunctivitis sicca (KCS), or dry eye syndromeMedDRA version: 9.1 Level: PT Classification code 10023350 Term: Keratoconjunctivitis siccaEUCTR2007-000029-23-GBovagali Pharma S.A.482